Kalydeco Granule
NDC 51167-300
Product Information
Kalydeco (ivacaftor) is a NDA-approved product labeled by Vertex Pharmaceuticals Incorporated. This medication is used to treat cystic fibrosis in certain people (those with an abnormal "CFTR" gene). It is supplied as a blue granule for oral administration. This product entry covers the primary NDC 51167-300 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
WHITE (C48325)
V;150
Code Structure Chart
Product Details
What is NDC 51167-300?
What are the uses of this product?
What are Active Ingredients of this product?
- IVACAFTOR 50 mg/1 - a CFTR potentiator; structure in first source
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- IVACAFTOR (UNII: 1Y740ILL1Z)
- IVACAFTOR (UNII: 1Y740ILL1Z) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MM2/S) (UNII: 6N003M473W)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- SODIUM LAURYL SULFATE (UNII: 368GB5141J)
- CARNAUBA WAX (UNII: R12CBM0EIZ)
- FD&C BLUE NO. 2 (UNII: L06K8R7DQK)
- POLYETHYLENE GLYCOL 3350 (UNII: G2M7P15E5P)
- POLYVINYL ALCOHOL, UNSPECIFIED (UNII: 532B59J990)
- TALC (UNII: 7SEV7J4R1U)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- AMMONIA (UNII: 5138Q19F1X)
- FERROSOFERRIC OXIDE (UNII: XM0M87F357)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- SHELLAC (UNII: 46N107B71O)
- MANNITOL (UNII: 3OWL53L36A)
- SUCRALOSE (UNII: 96K6UQ3ZD4)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1243046 - ivacaftor 150 MG Oral Tablet
- RxCUI: 1243052 - kalydeco 150 MG Oral Tablet
- RxCUI: 1243052 - ivacaftor 150 MG Oral Tablet [Kalydeco]
- RxCUI: 1243052 - Kalydeco 150 MG Oral Tablet
- RxCUI: 1606862 - ivacaftor 50 MG Oral Granules
Which are the Pharmacologic Classes of this product?
- Chloride Channel Activation Potentiators - [MoA] (Mechanism of Action)
- Cystic Fibrosis Transmembrane Conductance Regulator Potentiator - [EPC] (Established Pharmacologic Class)
- Cytochrome P450 2C9 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inhibitors - [MoA] (Mechanism of Action)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
* Please review the full disclaimer at the bottom of this page.
Patient Education
Ivacaftor
Ivacaftor is used to treat certain types of cystic fibrosis (an inborn disease that causes problems with breathing, digestion, and reproduction) in adults and children 4 months of age and older. Ivacaftor should be used only in people with a certain genetic make-up. Your doctor may order a blood test to help decide if this medication is right for you. Ivacaftor is in a class of medications called cystic fibrosis transmembrane conductance regulator (CFTR) potentiators. It works by improving the function of a protein in the body to decrease the build-up of thick mucus in the lungs and improving other symptoms of cystic fibrosis.
[Learn More]
* Please review the full disclaimer at the bottom of this page.